SCHEMBL16914461

SCHEMBL16914461

CC(C)(C)[S+]([O-])N[C@H]1CC[C@]12CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCNCC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21287146 0.91 — —
SCHEMBL30197731 0.91 — —
SCHEMBL22799019 0.91 — —
SCHEMBL16925168 0.91 — —
SCHEMBL18321898 0.91 — —
SCHEMBL30197607 0.91 — —
SCHEMBL21287260 0.91 — —
SCHEMBL18860310 0.91 — —
SCHEMBL22799001 0.90 — —
SCHEMBL22799003 0.90 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3094628-A1 N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 Novartis AG (CH) 2016-11-23 — — EP disclosed
WO-2015107495-A1 N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 NOVARTIS AG (CH) 2015-07-23 — — WO disclosed
Send feedback